Neurosense Therapeutics Ltd (NRSN) fell on Tuesday morning, the stock falling -4.97% pre-market to 3.63. NRSN’s short-term technical score of 69 indicates that the stock has traded more bullish over the past month than 69% of stocks on the market. In the biotech industry, which ranks 138th out of 146 industries, Neurosense Therapeutics Ltd ranks above 91% of the stock. Neurosense Therapeutics Ltd is up 152.98% over the past month, closing at $2.13 on March 1. During this period, the stock fell as low as $1.33 and as low as $8.18.
Neurosense Therapeutics Ltd has a long-term technical rating of 0. This means trading over the past 200 trading days has placed the company in the bottom half of the stock, with 100% of the market scoring higher. In the biotech industry which is number 132 by this metric, NRSN ranks better than 0% of stocks.
Important dates for investors in NRSN:
-We do not have a fixed pay date for Neurosense Therapeutics Ltd at this time. -We do not have a dividend date set for Neurosense Therapeutics Ltd at this time. Click here for the full report on Neurosense Therapeutics Ltd (NRSN)
Stay in the know
Subscribe to our daily morning update newsletter and never miss market news, moves and more.